Patents by Inventor Bernard Bihain
Bernard Bihain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7393661Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. This application pertains to nucleic acids encoding a compound, globular OBG3 polypeptide fragments, vectors and transformed host cells containing these nucleic acids and methods of making the globular OBG3 polypeptide fragments.Type: GrantFiled: May 19, 2005Date of Patent: July 1, 2008Assignee: Serono Genetics Institute S.A.Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen-Potin, Bernard Bihain
-
Patent number: 7371811Abstract: The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.Type: GrantFiled: June 6, 2005Date of Patent: May 13, 2008Assignee: Serono Genetics Institute S.A.Inventors: Daniel Cohen, Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Bernard Bihain, Laurent Essioux
-
Patent number: 7348406Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GMG-3, GMG-4, Cluster 1, GMG-6A, or GMG-6B polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: GrantFiled: January 15, 2002Date of Patent: March 25, 2008Assignee: Serono Genetics Institute S.A.Inventors: Mary Ruth Erickson, Barbara A. Chicca, Bernard Bihain, Hiroaki Tanaka
-
Patent number: 7338787Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: GrantFiled: October 20, 2004Date of Patent: March 4, 2008Assignee: Serono Genetics Institute S.A.Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen-Potin, Bernard Bihain
-
Patent number: 7326678Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GMG-3, GMG-4, Cluster 1, GMG-6A, or GMG-6B polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: GrantFiled: January 15, 2002Date of Patent: February 5, 2008Assignee: Serono Genetics Institute S.A.Inventors: Mary Ruth Erickson, Barbara A. Chicca, Bernard Bihain, Hiroaki Tanaka, Tom Chu, Deno P. Dialynas, Aaron Scalia
-
Publication number: 20070275891Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: ApplicationFiled: May 19, 2005Publication date: November 29, 2007Applicant: Genset S.A.Inventors: Joachim Fruebis, Mary Erickson, Frances Yen-Potin, Bernard Bihain
-
Patent number: 7291709Abstract: The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines.Type: GrantFiled: August 27, 2003Date of Patent: November 6, 2007Assignees: Serono Genetics Institute S.A., Institut National de la Sante de la Recherche Medicale (INSERM)Inventors: Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin
-
Patent number: 7223727Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GSSP4 polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing cholesterol levels, body mass, body fat, and for treating metabolic-related diseases and disorders. The metabolic-related diseases or disorders include, but are not limited to, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, diabetes, glucose intolerance, insulin resistance and hypertension.Type: GrantFiled: February 7, 2002Date of Patent: May 29, 2007Assignee: Serono Genetics Institute S.A.Inventors: Barbara Chicca, John Chicca, Blake Denison, Frances Yen-Potin, Bernard Bihain, Stephane Bejanin, Hiroaki Tanaka, Severin Jobert, Jean-Yves Giordano, Jean-Baptiste Dumas Milne Edwards
-
Patent number: 7220722Abstract: Methods and pharmaceutical compositions useful for treating obesity-related disorders using ApM-1 and related proteins.Type: GrantFiled: February 5, 2002Date of Patent: May 22, 2007Assignee: Serono Genetics Institute S.A.Inventors: Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin
-
Patent number: 7220581Abstract: The invention relates to polynucleotides of the PAPAP gene, polypeptides encoded by the PAPAP gene, and antibodies directed specifically against such polypeptides. The invention also concerns methods for the treatment or diagnosis of schizophrenia, bipolar disorder or related CNS disorder. The invention also concerns the interaction of PAPAP with schizophrenia candidate gene g34872.Type: GrantFiled: February 6, 2002Date of Patent: May 22, 2007Assignee: Serono Genetics Institute S.A.Inventors: Bernard Bihain, Barbara Bour, Lydie Bougueleret
-
Publication number: 20060247160Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GMG-3, GMG-4, Cluster 1, GMG-6A, or GMG-6B polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: ApplicationFiled: January 15, 2002Publication date: November 2, 2006Applicant: Genset S.A.Inventors: Mary Ruth Erickson, Barbara Chicca, Bernard Bihain, Hiroaki Tanaka
-
Patent number: 7125667Abstract: The invention provides novel LSR genomic sequences, polypeptides, antibodies, and polynucleotides including biallelic markers derived from the LSR locus. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.Type: GrantFiled: August 7, 2002Date of Patent: October 24, 2006Assignee: Serono Genetics Institute S.A.Inventors: Marta Blumenfeld, Lydie Bougueleret, Bernard Bihain
-
Patent number: 7122644Abstract: The invention provides the genomic sequence of GSSP-2, GSSP-2 cDNAs and GSSP-2 polypeptides. Further the invention provides polynucleotides including biallelic markers derived from the GSSP-2 gene and from genomic regions flanking the gene. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid molecule containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. The invention also concerns methods and compositions for killing neoplastic cells or inhibiting neoplastic cell growth. In particular, the present invention concerns cell proliferation arresting/inhibiting and apoptosis/necrosis inducing compositions and methods for the treatment of tumors. The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides.Type: GrantFiled: April 10, 2002Date of Patent: October 17, 2006Assignee: Serono Genetics Institute S.A.Inventors: Frances Yen-Potin, Blake Denison, Aymeric Duclert, Lydie Bougueleret, Catherine Clusel, Jean-Baptiste Dumas Milne Edwards, Bernard Bihain, Barbara Bour, Dana Ebbets-Reed, Luisa Salter-Cid
-
Publication number: 20060189793Abstract: The invention provides the genomic sequence of GSSP-2, GSSP-2 cDNAs and GSSP-2 polypeptdes. Further the invention provides polynucleotides including biallelic markers derived from the GSSP-2 gene and from genomic regions flanking the gene. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid molecule containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. The invention also concerns methods and compositions for killing neoplastic cells or inhibiting neoplastic cell growth. In particular, the present invention concerns cell proliferation arresting/inhibiting and apoptosis/necrosis inducing compositions and methods for the treatment of tumors. The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides.Type: ApplicationFiled: April 27, 2006Publication date: August 24, 2006Applicant: Serono Genetics Institute S.A.Inventors: Frances Yen, Blake Denison, Aymeric Duclert, Lydie Bougueleret, Catherine Clusel, Jean-Baptiste Dumas Milne-Edwards, Bernard Bihain, Barbara Bour, Dana Ebbets-Reed, Luisa Salter-Cid
-
Publication number: 20060166259Abstract: The invention provides novel APM1 genomic sequences, polypeptides, antibodies, and polynucleotides including biallelic markers derived from the APM1 locus. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Additionally, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. Further, the invention provides diagnostic methods for early detection of obesity-related disorders.Type: ApplicationFiled: March 28, 2006Publication date: July 27, 2006Applicant: Serono Genetics Institute S.A.Inventors: Lydie Bougueleret, Bernard Bihain, Blake Denison, Frances Yen-Potin
-
Patent number: 7067627Abstract: The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.Type: GrantFiled: May 16, 2002Date of Patent: June 27, 2006Assignee: Serono Genetics Institute S.A.Inventors: Daniel Cohen, Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Bernard Bihain, Laurent Essioux
-
Publication number: 20060035824Abstract: The present invention relates to the field of muscle research, in particular to the discovery of a compound effective for increasing muscle mass, muscle cell differentiation, and oxidation of free fatty acids in muscle, useful in methods of treating muscle-related diseases and disorders as well as for augmenting muscle mass in general. The muscle-related diseases or disorders envisaged to be treated by the methods of the invention include, but are not limited to, muscular dystrophy, and other conditions resulting in muscle atrophy or muscle wasting.Type: ApplicationFiled: May 22, 2001Publication date: February 16, 2006Applicant: GensetInventors: Harvey Lodish, Joachim Fruebis, Tsu-Shuen Tsao, Bernard Bihain
-
Publication number: 20060030530Abstract: The present invention is drawn to methods of screening for new compounds for the treatment of obesity and obesity-related diseases and disorders, as well as methods of treating obesity-related diseases and disorders, based on the discovery of the role of the leptin-LSR interaction in obesity.Type: ApplicationFiled: September 27, 2005Publication date: February 9, 2006Applicant: Serono Genetics Institute S.A.Inventors: Frances Yen, Bernard Bihain, Mary Erickson, Joachim Fruebis
-
Patent number: 6989367Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: GrantFiled: November 1, 2002Date of Patent: January 24, 2006Assignee: Genset S.A.Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen-Potin, Bernard Bihain
-
Publication number: 20050260667Abstract: The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.Type: ApplicationFiled: June 6, 2005Publication date: November 24, 2005Applicant: Genset S.A.Inventors: Daniel Cohen, Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Bernard Bihain, Laurent Essioux